Simcere Bio Announces RMB 150 Million Series C1 Financing to Accelerate Commercialization and Global Clinical Development

On November 8, 2022, Shanghai Sai Murrow Biotechnology Co., Ltd. (hereinafter referred to as “Sai Murrow Biotech” or the “Company”) announced that it had secured RMB 150 million in Series C1 financing and tens of millions of yuan in bank loans. This round of financing was jointly invested by Guanzi Venture Capital, Tianruifengnian, and Yixing Huarui. The proceeds are planned to be used to accelerate the clinical trials and international cooperation for multiple projects in the Company’s R&D pipeline, as well as to support the preclinical development of subsequent projects. Since its establishment, the Company has continuously received investments from numerous renowned institutions, including Shenzhen Capital Group, Cowin Capital, Zhangjiang Hi-Tech, GF Xinde, Yifeng Capital, Gaolin Capital, and Fengchuan Capital. The industrial value of the Company has gradually gained consensus and recognition in the capital market.

Shanghai Sai Murrow Biotechnology Co. Ltd., founded in 2014, is a global innovative biotechnology company driven by innovation. With a mission to alleviate and relieve patient suffering and improve quality of life, the company is dedicated to the research and development of novel therapeutics for pain, inflammation, and central nervous system-related disorders. Headquartered in Shanghai, China, the company has established branches in Guangdong and Jiangsu provinces, as well as in Australia and the United States. It has built China’s first comprehensive drug innovation and translation platform, filed nearly 100 domestic and international patents around its core products, and holds full independent intellectual property rights and global market rights.

To date, Sai Murrow Biotechnology has established eight internationally innovative drug pipelines. Three of its products—SR419, SR750, and SR1375—have become candidate drugs for global multicenter clinical trials spanning China, the United States, and Australia. Notably, SR419, an independently developed candidate drug with a novel mechanism of action for the treatment of peripheral neuropathic pain, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) and was granted Fast Track Designation (FTD) by the FDA in May 2022. Multiple international multicenter Phase II clinical trials evaluating SR419 and SR750 are currently underway. Recently, the international multicenter Phase II clinical trial for SR1375, an independently developed candidate drug with a novel mechanism of action for the treatment of neuroinflammation, also received approval from the U.S. FDA.

With over 20 years of technological accumulation and experience in the field of pain management, Shanghai Sai Murrow Biotechnology Co. Ltd. boasts a first-class R&D team, sustained innovation capabilities, and a clear business layout, which will undoubtedly drive the company to achieve continuous global breakthroughs in pain management and maintain its leading position in the international development of neuroinflammation drugs. As the clinical development of multiple Phase II/I products advances in China, the United States, and Australia, the company has entered a period of rapid business expansion, with numerous research achievements accelerating the commercialization process.

Guanzi Venture CapitalIt was stated that the global market size for neuropathic pain and mixed pain, the therapeutic areas in which Sai Murrow Biotechnology operates, amounts to tens of billions of US dollars. Given the multifaceted limitations of existing first-line therapies, the company’s product portfolio will provide comprehensive solutions for patients with chronic pain worldwide. Leveraging over two decades of accumulation in the field of pain management, Sai Murrow Biotechnology has achieved global breakthroughs in pain treatment and maintains a leading position globally in the field of neuroinflammation. With strong differentiated advantages and rapid clinical advancement, we are firmly optimistic about the future applications and market value of the company’s products in the fields of pain and inflammation.

Zhou Xiaojiao, Partner at Tianrui FengnianVCBeat stated, “Congratulations to the company on completing a new round of substantial financing. Amid the current cooling of overall investment in the biopharmaceutical industry, only truly high-quality assets can weather market cycles and gain sustained recognition. Sai Murrow Biotechnology focuses on the pain and inflammation therapeutic areas, which present high barriers to drug development. The company adheres to an R&D model centered on original target discovery and high-success-rate translational medicine. Its core product has entered Phase II clinical trials, representing a scarce asset globally. We believe that Sai Murrow Biotechnology will withstand tests and market cycles, forging ahead and thriving against the tide on the path to developing innovative new drugs.”

Dr. Li Shuai, Founder and CEO of Sai Murrow BiotechnologyThe company stated that over the past eight years since its establishment, it has completed a full trajectory spanning from foundational scientific research and translational medicine to Phase II clinical validation. It has built an internationally competitive clinical product pipeline focused on pain and inflammation, and has amassed a portfolio of central nervous system (CNS) drug candidates with significant market potential. We sincerely appreciate the recognition and support from both new and existing investors, which have provided strong momentum for the company’s future growth. As a China-based innovative pharmaceutical enterprise, Shanghai Sai Murrow Biotechnology Co., Ltd. remains committed to its mission of promoting Chinese indigenous innovative drugs on the global stage. Moving forward, we will continue to deepen our industrial research and development, delivering safer and more effective therapies to benefit patients in China and worldwide.